Securities Firms Maintain "Buy" Rating on Fosun International, Highlighting Significant Success in Business Streamlining Strategy and "Strategic Advancements and Exits"
HONG KONG, April 8, 2025 /PRNewswire/ -- Industrial Securities and Kaiyuan Securities recently published research reports highlighting Fosun International (00656.HK)'s accelerated exit from non-core assets and continued focus on core businesses. The...
Fosun International 2024 Annual Results Presentation: Aiming for RMB10 Billion in Future Industrial Operation Profit
HONG KONG and SHANGHAI, April 2, 2025 /PRNewswire/ -- On 1 April 2025, Fosun International Limited (HKEX stock code: 00656, "Fosun International"), together with its subsidiaries ("Fosun" or the "Group") held its 2024 annual results presentation in...
Guo Guangchang's Letter to Shareholders: Fosun International Pursues Progress through "Strategic Advancements and Exits"
HONG KONG, March 31, 2025 /PRNewswire/ -- Guo Guangchang, Chairman of Fosun International Limited (HKEX: 0656), issued a letter to its shareholders on 30 March, outlining the Company's strategic direction, accomplishments, and future plans. Dear...
Fosun International Announces 2024 Annual Results: Total Revenue Reaches RMB192.14 Billion, Industrial Operation Profit Amounts to RMB4.9 Billion, Overall Operational Fundamentals Remain Stable
2024 Annual Results Highlights: Total revenue reached RMB192.14 billion; Industrial operation profit amounted to RMB4.9 billion; Total revenue generated by the four core subsidiaries amounted to RMB134.65 billion, accounting for 70.1% of the Group's...
Fosun International Reports Total Revenue of RMB 192.14 Billion and Industrial Operation Profit of RMB 4.9 Billion in 2024
HONG KONG, March 30, 2025 /PRNewswire/ -- On 30 March 2025, Fosun International Limited (HKEX stock code: 00656) announced its annual results for the year 2024. During the period, the Group's total revenue reached RMB192.14 billion. Its four core...
Fosun Pharma Announces 2024 Annual Results
Accelerates Globalization of Innovative Products with Operating Cash Flow Surging 31.13% YoY SHANGHAI, March 26, 2025 /PRNewswire/ -- On March 25, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"or "the Group"; Stock Code:...
Sisram Medical to Report FY 2024 Financial Results on March 19 and Hold a Conference Call on March 20
FY 2024 conference call to be held on March 20, at 8:00 a.m. Eastern Time HONG KONG, March 13, 2025 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", stock code: 1696.HK; together with its subsidiaries referred as the "Group"), a global...
Raziel and Fosun Pharma (by JuveStar an affiliate company of Fosun Pharma) Initiate Phase 3 Registration Trial in China for Submental Fat Reduction ("double chin")
REROVOT, Israel, March 4, 2025 /PRNewswire/ -- Raziel Therapeutics, a pharmaceutical company developing next-generation novel prescription products for the medical aesthetics market, announces phase 3 study initiation in China for the treatment of...
Fosun Pharma Received NMPA Approval for Wan Ti Le (Tenapanor Hydrochloride Tablets)
Bringing New Hope to Chinese Dialysis Patients with Hyperphosphatemia SHANGHAI, Feb. 26, 2025 /PRNewswire/ -- Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma; stock code: 600196.SH, 02196.HK) announced that its holding subsidiary,...
BGM Group Welcomes Guilin Pharma for On-site Audit and Partnership Development
CHENGDU, China, Nov. 22, 2024 /PRNewswire/ -- On November 19, Qilianshan Pharmaceutical Co., Ltd. (Qilian Pharma), a subsidiary of BGM Group Ltd, welcomed a team of experts from Guilin Pharmaceutical Co., Ltd. (Guilin Pharma), including Quality...